DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta type 2 — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta type 2 maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type I alpha 1 chain (COL1A1) — COL1A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet eladrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7E7B · 2.6 Å · ligand Elaidic acid (ELA). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 1997 · 20 citations
Osteogenesis imperfecta
AbstractIn the past 20 years, tremendous strides have been made in our understanding of the biochemical and genetic abnormalities associated with osteogenesis imperfecta (OI). Prenatal diagnostic techniques have allowed early detection of this disorder, particularly in families in which the actual molecular defect is already known. Although medical and surgical management of patients with OI continue to improve, the proper management of such problems as basilar impression still need to be determined. Progress in the treatment of OI at a molecular level is encouraging.
AbstractThe purpose of this study was to determine if the severity of osteogenesis imperfecta (Ol) in childhood might have any influence on functional outcome. In a cross-sectional study, the functional outcome of 61 children with Ol was related to the three subtypes of the disease. Functional outcome was measured with the Dutch translation of the Pediatric Evaluation of Disability Inventory (PEDI). The PEDI measures capability and performance in three specific categories: “self-care, ” “mobility, ” and “social function.” We concluded that functional abilities, especially in the mobility category, were related to Ol subtype. The more severe the disease, the lower the score on mobility. In the self-care area, the score of all children ≤7.5 years of age, was within two standard deviations of the median. Despite severe disablement, children with Ol type III scored within the normal ranges. In older children with Ol, the relationship between Ol subtypes and functional ability became more pronounced. In children with the most severe disablement, there was a tendency, although not significant, for social function to be better developed. In children with a disease such as Ol, which affects posture, alignment, and growth, a severity-related functional ability profile seems to exist. Future multicenter research could further define a disease-related functional ability profile in Ol.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
